Figure S1: Examination of CD133 expression before and after shRNA-CD133 transducted into Capan1M9 cells.



	CD133/1-APC	CD133/1-PE	GFP
Capan-1M9	89.0	72.6	0
Capan-1M9/GFP	84.4	72.6	99.0
shCD133M9/GFP	20.6	-	97.8

Figure S2: In vivo experimental schedule for analysis of invasion and metastasis by the metastatic or orthotopic models.



Figure S3: The lung metastasis model created by the tail vein injection of Capan1M9-GFP or shCD133M9-GFP cells into nude mice.



Figure S4: Comparison of tumor-take rates between CD133^{high} and CD133^{KD} cells by subcutaneous xenograft tumor model



Comparison of tumor-take rate in nude mice between Capan-1M9 and shCD133M9 cells

Number of cells (s.c.)	**Capan-1M9**	**shCD133M9**
100 cells	5/5	5/5
1000 cells	5/5	5/5

(n=5)

Figure S5: Comparison of growth curves among the tumors generated by CD133^{high} and CD133^{KD} cells in xenograft models



Figure S6: Comparison of four week's tumor volumes between tumors generated by $CD133^{high}$ and $CD133^{KD}$ cells in pancreatic orthotopic model.



Figure S7: Transduction of shRNACD133 and shRNASlug into Capan1M9 cells. mRNA expression levels of CD133 and Slug were examined after shRNA transduction of CD133 or Slug into Capan1M9 cells (***left***). Fluorescent observation of GFP after shRNA transduction into Capan1M9 cells (***right***).



Figure S8: Validation of Slug expression after ERK or TGF inhibitor treatment. Slug mRNA expression was examined after ERK or TGF inhibitor (U0126 or SB431542) treatment.